AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23535987 — intervention group
Group type: COMPARATOR
Intervention: Visit-to-visit variability metrics (s.d., SDIM, CV, SV, ARV, range, maximum, peak size, trough size)
Number of subjects: 288
Study 21317771 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 9990
Study 21317771 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 9990
Study 21650071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside inoculation of culture media with CSF
Number of subjects: 220
Study 21650071 — intervention group
Group type: COMPARATOR
Intervention: Laboratory inoculation of culture media with CSF
Number of subjects: 220
Study 16981176 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for measurement error using regression calibration
Number of subjects: 0
Study 15034156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20
Study 15034156 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 20
Study 11605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 0 breaths/min
Number of subjects: 11
Study 11605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 5 breaths/min
Number of subjects: 11
Study 11605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 10 breaths/min
Number of subjects: 11
Study 11605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 15 breaths/min
Number of subjects: 11
Study 11605928 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) at 20 breaths/min
Number of subjects: 11
Study 9682686 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO members in the intervention group
Number of subjects: 2316
Study 9682686 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HMO patients in the intervention group
Number of subjects: 2316
Study 8202788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12-week duration)
Number of subjects: 37
Study 8202788 — intervention group
Group type: COMPARATOR
Intervention: Untrained control subjects (no aerobic exercise)
Number of subjects: 37
Study 2532458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1 mg once daily for 4 weeks, then increased to 2.5 mg once daily for 4 weeks, and further increased to 5 mg if necessary
Number of subjects: 83
Study 2532458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 83
Study 1055560 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO spray (2 ml applied in the posterior pharynx and tonsil region, 1 to 4 applications)
Number of subjects: 60
Study 1055560 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO spray
Number of subjects: 60
Study 1055560 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar treatment without DMSO spray)
Number of subjects: 60
Study 29867044 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention using a specially designed internet platform and educational materials prepared by a physician specialized in clinical oncology.
Number of subjects: 463
Study 29867044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 463
Study 29798102 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan nerve conduit with PRP (Group A)
Number of subjects: 40
Study 29798102 — intervention group
Group type: COMPARATOR
Intervention: Chitosan nerve conduit with saline (Group B)
Number of subjects: 40
Study 29798102 — intervention group
Group type: COMPARATOR
Intervention: Silicone tube with saline (Group C)
Number of subjects: 40
Study 29798102 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tube with PRP (Group D)
Number of subjects: 40
Study 26099756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 81
Study 26099756 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 81
Study 26099756 — intervention group
Group type: COMPARATOR
Intervention: Combination of CFNB and ITM
Number of subjects: 81
Study 22746542 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) supplementation (250 mg, 2 b.i.d.)
Number of subjects: 92
Study 22746542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 21232162 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioural therapy
Number of subjects: 0
Study 21232162 — intervention group
Group type: COMPARATOR
Intervention: Online attention control placebo
Number of subjects: 0
Study 19028952 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 ml placebo gel
Number of subjects: 77
Study 19028952 — intervention group
Group type: COMPARATOR
Intervention: 8 g placebo rectal suppositories
Number of subjects: 77
Study 16855180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 5145
Study 16855180 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 5145
Study 12556780 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal stent
Number of subjects: 118
Study 12556780 — intervention group
Group type: COMPARATOR
Intervention: Plastic stent
Number of subjects: 118
Study 10671393 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 57
Study 10671393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 57
Study 10671393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8848990 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study 8848990 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 1593410 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate (100 mg)
Number of subjects: 99
Study 1593410 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (500 mg)
Number of subjects: 99
Study 1593410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 6146164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2 mg)
Number of subjects: 11
Study 30078111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + D-cycloserine (DCS)
Number of subjects: 24
Study 30078111 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) + Placebo
Number of subjects: 24
Study 29970184 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 30
Study 29970184 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 30
Study 29970184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26727682 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) using pillows
Number of subjects: 60
Study 26727682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Positioning System (PPS)
Number of subjects: 60
Study 24602520 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus LED sealants
Number of subjects: 405
Study 24602520 — intervention group
Group type: COMPARATOR
Intervention: Resin-composite sealants
Number of subjects: 405
Study 24602520 — intervention group
Group type: COMPARATOR
Intervention: Glass-carbomer sealants
Number of subjects: 405
Study 24602520 — intervention group
Group type: COMPARATOR
Intervention: Conventional ART sealants
Number of subjects: 405
Study 24602520 — intervention group
Group type: COMPARATOR
Intervention: Free smooth surfaces (all groups)
Number of subjects: 405
Study 22783709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1 g three times daily
Number of subjects: 120
Study 22783709 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg twice daily
Number of subjects: 120
Study 22783709 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NaCl)
Number of subjects: 120
Study 22783709 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g three times daily
Number of subjects: 120
Study 20831534 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone therapy
Number of subjects: 1054
Study 20831534 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administered parenterally by intermittent or continuous infusions
Number of subjects: 1054
Study 20831534 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion route of naloxone
Number of subjects: 1054
Study 17506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine PCA
Number of subjects: 60
Study 17506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol PCA
Number of subjects: 60
Study 17506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg IM
Number of subjects: 60
Study 16225538 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard circumcision procedure
Number of subjects: 479
Study 12052801 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (yeast: Saccharomyces boulardii)
Number of subjects: 9
Study 12052801 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (lactobacilli)
Number of subjects: 9
Study 12052801 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined probiotics
Number of subjects: 9
Study 12052801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9866849 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemia patients
Number of subjects: 113
Study 9866849 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 8721892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 75
Study 8721892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 75
Study 8721892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 2709305 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 6
Study 2709305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 332319 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC alone
Number of subjects: 415
Study 332319 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl‐CCNU alone
Number of subjects: 415
Study 332319 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus methyl‐CCNU
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: Responders
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: methyl‐CCNU
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: Combination DTIC plus methyl‐CCNU
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: Favorable characteristics
Number of subjects: 415
Study 332319 — intervention group
Group type: COMPARATOR
Intervention: Unfavorable characteristics
Number of subjects: 415
Study 6262148 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV) combined with concentrated diphtheria and tetanus toxoid, administered in one or two injections at an interval of 6 months.
Number of subjects: 0
Study 6262148 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine C (higher concentration)
Number of subjects: 0
Study 6262148 — intervention group
Group type: COMPARATOR
Intervention: Oral polio vaccine (OPV), 4 doses in 15 months (control group)
Number of subjects: 0
Study 30835956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous adipose-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 24
Study 30835956 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 24
Study 29138794 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation plus noninvasive testing (CCTA or stress test)
Number of subjects: 1000
Study 29138794 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation alone
Number of subjects: 1000
Study 27018862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity lower limb cycling for 30 minutes
Number of subjects: 12
Study 27018862 — intervention group
Group type: COMPARATOR
Intervention: Rest control condition for 30 minutes
Number of subjects: 12
Study 25135262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid 5% cream
Number of subjects: 0
Study 25135262 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone 0.1% cream
Number of subjects: 0
Study 21571394 — intervention group
Group type: EXPERIMENTAL
Intervention: Balicatib
Number of subjects: 709
Study 21571394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 21571394 — intervention group
Group type: COMPARATOR
Intervention: Lowest balicatib dose
Number of subjects: 709
Study 19053988 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 886
Study 19053988 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg
Number of subjects: 886
Study 17197313 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 20
Study 17197313 — intervention group
Group type: COMPARATOR
Intervention: Midvastus approach
Number of subjects: 20
Study 15681524 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus immediate androgen suppression (LHRH agonist)
Number of subjects: 173
Study 15681524 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone with hormonal manipulation at time of relapse
Number of subjects: 173
Study 15681524 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy and immediate hormonal manipulation
Number of subjects: 173
Study 12017317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg daily)
Number of subjects: 200
Study 12017317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10360303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract extraction and lens implantation
Number of subjects: 35
Study 10360303 — intervention group
Group type: COMPARATOR
Intervention: Cataract extraction, lens implantation, and trabeculectomy
Number of subjects: 35
Study 7813375 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical local excision
Number of subjects: 10
Study 2529799 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 5 mg plus pseudoephedrine 120 mg
Number of subjects: 283
Study 2529799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 3094 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 23
Study 3094 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 23
Study 31403958 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise program (MAE)
Number of subjects: 40
Study 31403958 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (HEP)
Number of subjects: 40
Study 28403018 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylatropine (500 μg)
Number of subjects: 60
Study 28403018 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study 25970942 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational chronic stress exposure (OCS)
Number of subjects: 60
Study 25970942 — intervention group
Group type: COMPARATOR
Intervention: Maladaptive cardiovascular response (MCVR)
Number of subjects: 60
Study 23919595 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine implants (BI)
Number of subjects: 114
Study 23919595 — intervention group
Group type: COMPARATOR
Intervention: Placebo implants (PI)
Number of subjects: 114
Study 23919595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone tablets (BNX)
Number of subjects: 114
Study 21900185 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cTnT at baseline
Number of subjects: 288
Study 21900185 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin conversion (from negative to detectable)
Number of subjects: 288
Study 21900185 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cTnT levels
Number of subjects: 288
Study 19226191 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (epoprostenol, Flolan) at a dose of 0.5 ng/kg/min
Number of subjects: 48
Study 19226191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17382651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolife O'Brien stentless valve
Number of subjects: 78
Study 17382651 — intervention group
Group type: COMPARATOR
Intervention: Toronto stentless valve
Number of subjects: 78
Study 15321031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sol to gel systems
Number of subjects: 15
Study 15321031 — intervention group
Group type: COMPARATOR
Intervention: Marketed eye drops
Number of subjects: 15
Study 10867450 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg, 40 mg t.i.d.)
Number of subjects: 309
Study 10867450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 9292454 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD mode (normal increase in heart rate)
Number of subjects: 10
Study 9292454 — intervention group
Group type: EXPERIMENTAL
Intervention: DOO‐Rest (HR fixed at resting value)
Number of subjects: 10
Study 9292454 — intervention group
Group type: EXPERIMENTAL
Intervention: DOO‐Ex (HR fixed at peak exercise rate)
Number of subjects: 10
Study 8243374 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 73
Study 3517076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 24
Study 3517076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (pindolol 15 mg + hydrochlorothiazide 50 mg)
Number of subjects: 24
Study 3517076 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 15 mg
Number of subjects: 24
Study 30803532 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% tetracaine plus 0.05% oxymetazoline (Kovanaze) nasal spray and mock infiltration
Number of subjects: 50
Study 30803532 — intervention group
Group type: COMPARATOR
Intervention: Mock nasal spray and 2% lidocaine with 1:100,000 epinephrine infiltration
Number of subjects: 50
Study 28421628 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (n=110)
Number of subjects: 220
Study 28421628 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (n=110)
Number of subjects: 220
Study 28421628 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 220
Study 28421628 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 220
Study 25550228 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylthioninium (MT) 138 mg/day
Number of subjects: 321
Study 25550228 — intervention group
Group type: COMPARATOR
Intervention: Methylthioninium (MT) 69 mg/day and 228 mg/day
Number of subjects: 321
Study 23451070 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 in neonatal schedule (0-1-2 months)
Number of subjects: 318
Study 23451070 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 in infant schedule (1-2-3 months)
Number of subjects: 318
Study 23451070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCV7)
Number of subjects: 318
Study 23451070 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV at age 9 months
Number of subjects: 318
Study 20888912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rapid corticosteroid reduction to 10 mg/day seven days post-transplantation
Number of subjects: 0
Study 20888912 — intervention group
Group type: COMPARATOR
Intervention: Standard corticosteroid therapy
Number of subjects: 0
Study 20888912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rapid corticosteroid reduction
Number of subjects: 0
Study 17520253 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administered orally twice daily after meals at a dose of 80, 100, or 120 mg/day for body surface areas (BSAs) of less than 1.25 m(2), between 1.25 m(2) and less than 1.5, or 1.5 m(2) or greater, respectively, for 28 consecutive days, followed by a 14-day rest
Number of subjects: 40
Study 17520253 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 40
Study 16202394 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers from the Canadian study (8 markers)
Number of subjects: 450
Study 16202394 — intervention group
Group type: COMPARATOR
Intervention: Supernormal controls
Number of subjects: 450
Study 12936917 — intervention group
Group type: COMPARATOR
Intervention: Butter-enriched diet (low in trans FAs, 2.6 g trans FAs/100 g fat)
Number of subjects: 36
Study 12936917 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiliquid margarine (0.6 g trans FAs/100 g fat)
Number of subjects: 36
Study 12936917 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft margarine (9.4 g trans FAs/100 g fat)
Number of subjects: 36
Study 12936917 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening (13.6 g trans FAs/100 g fat)
Number of subjects: 36
Study 12936917 — intervention group
Group type: EXPERIMENTAL
Intervention: Stick margarine (26.1 g trans FAs/100 g fat)
Number of subjects: 36
Study 10541929 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (12 weeks, 3 days/week, four lower-body exercises)
Number of subjects: 2
Study 10541929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2
Study 9345420 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly for 6 months
Number of subjects: 0
Study 9345420 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly for 6 months
Number of subjects: 0
Study 9345420 — intervention group
Group type: COMPARATOR
Intervention: Placebo given thrice weekly for 6 months
Number of subjects: 0
Study 2052380 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 53
Study 2052380 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 53
Study 2052380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 2052380 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine with acetaminophen (2 combinations)
Number of subjects: 53